1. Home
  2. IBRX vs CSTM Comparison

IBRX vs CSTM Comparison

Compare IBRX & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • CSTM
  • Stock Information
  • Founded
  • IBRX 2014
  • CSTM 2010
  • Country
  • IBRX United States
  • CSTM France
  • Employees
  • IBRX N/A
  • CSTM N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • CSTM Metal Fabrications
  • Sector
  • IBRX Health Care
  • CSTM Industrials
  • Exchange
  • IBRX Nasdaq
  • CSTM Nasdaq
  • Market Cap
  • IBRX 2.3B
  • CSTM 2.1B
  • IPO Year
  • IBRX N/A
  • CSTM 2013
  • Fundamental
  • Price
  • IBRX $2.58
  • CSTM $16.91
  • Analyst Decision
  • IBRX Strong Buy
  • CSTM Hold
  • Analyst Count
  • IBRX 6
  • CSTM 1
  • Target Price
  • IBRX $9.83
  • CSTM $16.00
  • AVG Volume (30 Days)
  • IBRX 9.7M
  • CSTM 1.1M
  • Earning Date
  • IBRX 11-10-2025
  • CSTM 10-29-2025
  • Dividend Yield
  • IBRX N/A
  • CSTM N/A
  • EPS Growth
  • IBRX N/A
  • CSTM N/A
  • EPS
  • IBRX N/A
  • CSTM 0.22
  • Revenue
  • IBRX $56,600,000.00
  • CSTM $7,605,000,000.00
  • Revenue This Year
  • IBRX $629.94
  • CSTM $9.45
  • Revenue Next Year
  • IBRX $109.91
  • CSTM $4.91
  • P/E Ratio
  • IBRX N/A
  • CSTM $76.62
  • Revenue Growth
  • IBRX 4227.22
  • CSTM 2.04
  • 52 Week Low
  • IBRX $1.83
  • CSTM $7.33
  • 52 Week High
  • IBRX $6.82
  • CSTM $17.34
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 54.54
  • CSTM 63.98
  • Support Level
  • IBRX $2.30
  • CSTM $16.74
  • Resistance Level
  • IBRX $2.67
  • CSTM $17.34
  • Average True Range (ATR)
  • IBRX 0.12
  • CSTM 0.67
  • MACD
  • IBRX 0.01
  • CSTM 0.15
  • Stochastic Oscillator
  • IBRX 75.68
  • CSTM 85.13

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About CSTM Constellium SE (France)

Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.

Share on Social Networks: